Staidson (Beijing) BioPharmaceuticals Co EBIT per Share
The EBIT per Share of Staidson (Beijing) BioPharmaceuticals Co (300204.SZ) as of Oct 23, 2026 is -0.06 CNY. In the previous year, EBIT per Share was -0.77 CNY — a change of -91.57% (higher).
Get this data via API
Financial Data API
EBIT per Share
-0.06CNY
YoY
-91.57%
Last updated:
The Staidson (Beijing) BioPharmaceuticals Co EBIT per Share history
3 Years
10 Years
25 Years
Max
| YEAR | EBIT per Share | YoY |
|---|---|---|
| est | 0.04CNY | -157.17% |
| -0.06CNY | -91.57% | |
| -0.77CNY | +62.54% | |
| -0.47CNY | +10.23% | |
| -0.43CNY | +37.24% | |
| -0.31CNY | -790.80% | |
| 0.05CNY | -85.23% | |
| 0.31CNY | -51.14% | |
| 0.63CNY | +3.89% | |
| 0.60CNY | +19.82% | |
| 0.50CNY | +19.38% | |
| 0.42CNY | +56.26% | |
| 0.27CNY | -23.30% | |
| 0.35CNY | +13.80% | |
| 0.31CNY | +70.81% | |
| 0.18CNY | +155.28% | |
| 0.07CNY | +106.39% | |
| 0.03CNY | +361.38% | |
| 0.01CNY | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Staidson (Beijing) BioPharmaceuticals Co Stock analysis
Frequently Asked Questions about Staidson (Beijing) BioPharmaceuticals Co stock
EBIT per Share of Staidson (Beijing) BioPharmaceuticals Co is -0.06 CNY in 2024.
EBIT per Share of Staidson (Beijing) BioPharmaceuticals Co changed from -0.77 CNY to -0.06 CNY, representing a -91.57% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Staidson (Beijing) BioPharmaceuticals Co since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Staidson (Beijing) BioPharmaceuticals Co
All Key Metrics — Staidson (Beijing) BioPharmaceuticals Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth